Pregnancy and Neonatal Outcomes in COVID-19 (PAN-COVID) – a global registry of women with suspected or confirmed SARS-CoV-2 infection in pregnancy and their neonates, understanding natural history to guide treatment and prevention
Site and lead:
- Oxford Road Campus: Dr Samantha Ratcliffe
Patient group: Pregnant or postnatal women and/or their neonate with suspected or confirmed COVID-19
Sponsor: Imperial College of Science, Technology and Medicine
More about PAN-COVID
- PAN-COVID is a nationally-prioritised COVID-19 study. See the full list Urgent Public Health COVID-19 Studies on the NIHR website.
The purpose of this study is to better understand some specific research questions as to how COVID-19 affects early pregnancy, fetal growth, prematurity and virus transmission to the baby.
COVID-19 is likely to affect hundreds of pregnant women globally; Middle Eastern Respiratory Syndrome (MERS) and Severe Acute Respiratoy Syndrome (SARS), also coronaviruses, caused more severe illness, particularly lung infections, in pregnant vs. non-pregnant women.
PAN-COVID will develop a global database detailing a number of outcomes (death of the baby or mother, stillbirth, miscarriage, pregnancy complications etc). The aim of this database is to understand the natural history of SARS-CoV-2 and COVID-19 and the impact on mothers and their babies to guide both treatment and prevention.